Cargando…

The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials

Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPis) belong to a class of targeted drugs developed for the treatment of homologous recombination repair (HRR)-defective tumors. Preclinical and limited clinical data suggest that PARP inhibition is effective against prostate cancer (PC) i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Mingyue, Guo, Zhigang, Hu, Zhigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150298/ https://www.ncbi.nlm.nih.gov/pubmed/34066020 http://dx.doi.org/10.3390/biom11050722

Ejemplares similares

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

Recent advancements in PARP inhibitors-based targeted cancer therapy
por: Zhou, Ping, et al.
Publicado: (2020)

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
por: Teyssonneau, Diego, et al.
Publicado: (2022)

Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
por: Franchet, Camille, et al.
Publicado: (2021)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
por: McNevin, Ciara S., et al.
Publicado: (2022)

Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
por: Divan, Ali, et al.
Publicado: (2020)

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer
por: Chen, Hongjie, et al.
Publicado: (2023)

PARP inhibitors: its role in treatment of cancer
por: Chen, Alice
Publicado: (2011)

Prostate cancer and PARP inhibitors: progress and challenges
por: Teyssonneau, Diego, et al.
Publicado: (2021)

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
por: Virtanen, Verneri, et al.
Publicado: (2019)

Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel
por: Xia, Mingyue, et al.
Publicado: (2022)

Corrigendum: Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel
por: Xia, Mingyue, et al.
Publicado: (2023)

PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
por: Kim, Dongha, et al.
Publicado: (2022)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
por: Carreira, Suzanne, et al.
Publicado: (2021)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
por: Nizialek, Emily, et al.
Publicado: (2020)

Advances in using PARP inhibitors to treat cancer
por: Kummar, Shivaani, et al.
Publicado: (2012)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
por: Inderjeeth, Andrisha-Jade, et al.
Publicado: (2022)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
por: Marques, Maud, et al.
Publicado: (2015)

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
por: Reinbolt, Raquel E., et al.
Publicado: (2013)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

PARP and PARG inhibitors in cancer treatment
por: Slade, Dea
Publicado: (2020)

PARP Inhibitors: A New Horizon for Patients with Prostate Cancer
por: Congregado, Belén, et al.
Publicado: (2022)

Advances in the use of PARP inhibitor therapy for breast cancer
por: McCann, Kelly E, et al.
Publicado: (2018)

Pilot Study: PARP1 Imaging in Advanced Prostate Cancer
por: Dehdashti, Farrokh, et al.
Publicado: (2022)

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
por: Revythis, Antonios, et al.
Publicado: (2022)

A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer
por: Alameddine, Zakaria, et al.
Publicado: (2023)

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
por: Wang, Yizi, et al.
Publicado: (2020)

Use of PARP inhibitors in prostate cancer: from specific to broader application
por: Zhang, Zhenting, et al.
Publicado: (2023)

An Overview of PARP Inhibitors for the Treatment of Breast Cancer
por: Cortesi, Laura, et al.
Publicado: (2021)

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
por: Ledermann, Jonathan A, et al.
Publicado: (2015)

Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus
por: Redondo, Andrés, et al.
Publicado: (2023)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
por: Jiang, Xuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o89gol8d9bpmar9j3k05c2no8l